Concepedia

Publication | Open Access

Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer

DOIFull Paper Access

175

Citations

9

References

2020

Year

Hope S. Rugo, Fabrice André, Toshinari Yamashita, Humberto Cerda, I. Toledano, Salomon M. Stemmer, Josefina Cruz Jurado, Dejan Juric, Ingrid A. Mayer, Eva Ciruelos,
Annals of Oncology

Abstract

NCT02437318.

References

YearCitations

Page 1